<p><strong>Jaguar Health Inc</strong>（JAGX）股价在周二交易中下跌 10%，至 1.08 美元，此举是在公司公布比预期更糟糕的第二季度业绩后。</p>
<h2>发生了什么？</h2>
<p>Jaguar Health 的每股亏损为 4.04 美元，远远高于分析师共识预期的每股亏损 1.11 美元。</p>
<p>公司第二季度销售额为 272 万美元，比分析师共识预期的 394 万美元低 31%。然而，这一数字较去年同期的 268 万美元销售额略有增长 1.6%。</p>
<p>Jaguar Health 的 Mytesi 处方销量比 2024 年第一季度增长了 5.2%，尽管同比略有下降。在财务方面，与 2023 年第二季度相比，Jaguar 将净亏损降低 260 万美元至 950 万美元。</p>
<p>营运亏损减少了 90 万美元，研发费用减少了 60 万美元，这是由于其 OnTarget 临床试验的逐渐收尾。与此同时，该公司计划于 2024 年 10 月商业推出其获得 FDA 批准的 Gelclair，并继续开发罕见疾病的治疗方案。</p>
<p><strong><em>阅读更多：星巴克任命 Chipotle Mexican Grill 资深人士为新 CEO，股价飙升</em></strong></p>
<h2>我应该出售我的 JAGX 股票吗？</h2>
<p>是否出售或持有股票在很大程度上取决于投资者的策略和风险承受能力。波段交易者可能会出售表现优异的股票以锁定资本收益，而长期投资者可能会在预期股价进一步增长的情况下持有股票。</p>
<p>同样，愿意减少损失的交易者可能会出售下跌一定百分比的股票，而长期投资者可能会将此视为以折扣价购买更多股票的机会。</p>
<p>投资者还可以考虑市场动态。相对强弱指数可用于指示股票是超买还是超卖。Jaguar Health 股票目前的 RSI 为 60.97，表明中性条件。</p>
<p>有关分析工具、图表数据和独家股票新闻的获取，请查看 Benzinga PRO。免费试用。</p>
<p>JAGX 的 52 周最高价为 35.34 美元，52 周最低价为 1.03 美元。</p>

JAGX

<p>Jaguar Health (JAGX) 股价下跌 15%，因为其第二季度业绩低于预期。该公司每股亏损 4.04 美元，销售额为 272 万美元，未达到分析师的预期。然而，Jaguar Health 计划于 2024 年 10 月推出获得 FDA 批准的 Gelclair，并继续研发罕见疾病的治疗方案</p>

<p><strong>Jaguar Health Inc</strong> JAGX shares are trading lower by 10% to $1.08 during Tuesday’s session after the company reported worse-than-expected second-quarter results.</p>
<div class="lb-trans"><p><strong>Jaguar Health Inc</strong>（JAGX）股价在周二交易中下跌 10%，至 1.08 美元，此举是在公司公布比预期更糟糕的第二季度业绩后。</p>
</div><h2>What Happened?</h2>
<div class="lb-trans"><h2>发生了什么？</h2>
</div><p>Jaguar Health posted a loss of $4.04 per share, which came in worse than the analyst consensus estimate of a loss of $1.11 per share. ]</p>
<div class="lb-trans"><p>Jaguar Health 的每股亏损为 4.04 美元，远远高于分析师共识预期的每股亏损 1.11 美元。</p>
</div><p>The company reported quarterly sales of $2.72 million, falling short of the analyst consensus estimate of $3.94 million by 31%. However, this figure reflects a slight increase of 1.6% from the $2.68 million in sales reported in the same quarter of the previous year.</p>
<div class="lb-trans"><p>公司第二季度销售额为 272 万美元，比分析师共识预期的 394 万美元低 31%。然而，这一数字较去年同期的 268 万美元销售额略有增长 1.6%。</p>
</div><p>The company's Mytesi prescription volume rose by 5.2% from first-quarter 2024, though it saw a slight year-over-year decline. Financially, Jaguar reduced its net loss by $2.6 million to $9.5 million compared to second-quarter 2023.</p>
<div class="lb-trans"><p>Jaguar Health 的 Mytesi 处方销量比 2024 年第一季度增长了 5.2%，尽管同比略有下降。在财务方面，与 2023 年第二季度相比，Jaguar 将净亏损降低 260 万美元至 950 万美元。</p>
</div><p>Operating losses decreased by $0.9 million, and R&amp;D expenses fell by $0.6 million due to the winding down of its OnTarget clinical trial. The company meanwhile plans a commercial launch of its FDA-approved Gelclair in October 2024 and continues to develop treatments for rare diseases.</p>
<div class="lb-trans"><p>营运亏损减少了 90 万美元，研发费用减少了 60 万美元，这是由于其 OnTarget 临床试验的逐渐收尾。与此同时，该公司计划于 2024 年 10 月商业推出其获得 FDA 批准的 Gelclair，并继续开发罕见疾病的治疗方案。</p>
</div><p><strong><em>Read Also: Starbucks Appoints Chipotle Mexican Grill Veteran As New CEO, Stock Soars</em></strong></p>
<div class="lb-trans"><p><strong><em>阅读更多：星巴克任命 Chipotle Mexican Grill 资深人士为新 CEO，股价飙升</em></strong></p>
</div><h2>Should I Sell My JAGX Stock?</h2>
<div class="lb-trans"><h2>我应该出售我的 JAGX 股票吗？</h2>
</div><p>Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.</p>
<div class="lb-trans"><p>是否出售或持有股票在很大程度上取决于投资者的策略和风险承受能力。波段交易者可能会出售表现优异的股票以锁定资本收益，而长期投资者可能会在预期股价进一步增长的情况下持有股票。</p>
</div><p>Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.</p>
<div class="lb-trans"><p>同样，愿意减少损失的交易者可能会出售下跌一定百分比的股票，而长期投资者可能会将此视为以折扣价购买更多股票的机会。</p>
</div><p>Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health stock currently has an RSI of 60.97, indicating neutral conditions.</p>
<div class="lb-trans"><p>投资者还可以考虑市场动态。相对强弱指数可用于指示股票是超买还是超卖。Jaguar Health 股票目前的 RSI 为 60.97，表明中性条件。</p>
</div><p>For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.</p>
<div class="lb-trans"><p>有关分析工具、图表数据和独家股票新闻的获取，请查看 Benzinga PRO。免费试用。</p>
</div><p>JAGX has a 52-week high of $35.34 and a 52-week low of $1.03.</p>
<div class="lb-trans"><p>JAGX 的 52 周最高价为 35.34 美元，52 周最低价为 1.03 美元。</p>
</div>

为什么 Jaguar Health (JAGX) 的股票下跌了 15%？